Independent specialty pharmaciesNew

What gets pre-loaded

• preferenceimportance 9/10

  DEA-controlled-substance reconciliation — every Schedule II-V dispensing event triggers a structured 24-hour named-pharmacist + named-tech double-count with named DEA Form 222 / electronic CSOS reconciliation against perpetual inventory at named close-of-business

  Specialty pharmacies dispensing Schedule II-V controlled substances (oncology pain management, fertility hormonal protocols, named compounded controls) operate under DEA registrant obligations — every Schedule II receipt requires a named DEA Form 222 OR named CSOS electronic order with the named registrant's signature, every dispensing event reduces perpetual inventory, and any reconciliation discrepancy >0.001% triggers DEA-registrant reporting obligations. Operators that let perpetual-inventory reconciliation drift (a tech logs a dispensing event without the named pharmacist signature, a Form 222 receipt is filed without the matching inventory increment) routinely face DEA audit findings that escalate to license-suspension actions. The right practice rule is: every Schedule II-V dispensing event triggers a same-shift named-pharmacist + named-tech double-count with named patient + named prescriber + named DEA registration + named lot + named NDC at point of dispense, AND named close-of-business reconciliation matching perpetual inventory against physical count with any variance triggering same-day named-pharmacist investigation. Surface a watch item on any Schedule II receipt >24 hours old without a logged Form 222/CSOS reconciliation entry, AND any perpetual-inventory variance flagged on close-of-business that has not been resolved within 48 hours.

• preferenceimportance 9/10

  Named-pharmacist-of-record continuity — every named patient on long-term specialty therapy carries a named primary pharmacist + named secondary pharmacist with named handoff protocol at every named-prescription refill, named-prescriber clarification, AND named-cleared adverse event

  Specialty pharmacy patients on long-term therapy (oncology, fertility, immunoglobulin, biologics) form trust relationships with the named pharmacist who counseled them at therapy initiation — they ask the same pharmacist follow-up questions, they trust that pharmacist's named-prescriber communication, they call that pharmacist when an adverse event surfaces. Operators that rotate pharmacist-of-record opportunistically (covering for callouts, balancing pharmacist workload during named immunisation drives) routinely face named-patient escalations ('the new pharmacist didn't know about my history with X') that read as a clinical-care lapse even when the work quality is unchanged. The right practice rule is: every named patient on long-term specialty therapy carries (a) named primary pharmacist with named clinical familiarity, (b) named secondary pharmacist with documented handoff at therapy initiation, AND (c) named handoff protocol at every refill / prescriber clarification / adverse-event-clearance event. Surface a watch item when the named primary pharmacist has been unreachable for >5 business days without a logged named-secondary handoff, AND any named patient inquiry routed to a non-named pharmacist without a logged warm handoff reason.

• lessonimportance 9/10

  340B program-eligible patient red flag — any covered-entity-affiliated patient dispensing event without a logged 340B eligibility determination puts the named pharmacy at near-certain risk of HRSA audit findings + retroactive payback obligations

  Specialty pharmacies participating in the 340B Drug Pricing Program receive named discounts on covered outpatient drugs in exchange for named compliance with HRSA's covered-entity-eligibility rules — every dispensing event tied to a 340B-eligible patient must be matched to (a) named covered-entity affiliation at the time of named-prescriber visit, (b) named outpatient setting (no inpatient diversion), (c) named patient relationship documented at the named covered-entity, AND (d) named auditable record retained for 7 years. Operators that let 340B eligibility-determination drift (a patient changes named covered-entity affiliation mid-therapy without a re-determination, a named-prescriber writes from a non-affiliated location and the dispense is still claimed at 340B pricing) routinely face HRSA audit findings that include retroactive payback obligations PLUS named-program-removal risk. The right practice rule is: every 340B claim triggers a structured eligibility determination naming (a) named patient + named covered-entity affiliation + named-prescriber location + named therapy continuation status, (b) named auditable documentation timestamped at dispense, AND (c) named monthly eligibility re-verification on every active 340B patient. Surface a watch item on any 340B dispense within 30 days of a named-prescriber location change without a re-verification, AND any 340B claim flagged in the named monthly audit with an eligibility-determination gap.

• lessonimportance 8/10

  HIPAA-bound communication red flag — any specialty patient communication via unencrypted channel (SMS to a non-validated number, social DM, voicemail to a shared family line) without documented patient-consent risk-acknowledgement puts the firm at near-certain risk of HHS OCR breach reporting

  Specialty pharmacy patient communications carry HIPAA Protected Health Information — refill confirmations, adverse-event follow-ups, prior-authorization status updates, named-therapy reminders. Operators that let staff use unencrypted channels (SMS to a phone number the named patient hasn't consented to, social DMs that aren't covered by a named BAA, voicemail messages that name the therapy on a shared family line) routinely face HHS OCR breach-reporting obligations + state-attorney-general reporting that escalate within 60 days of the named incident. The right practice rule is: every named patient communication channel triggers a structured intake naming (a) named consent on file (paper or electronic with named timestamp), (b) named encryption status (named encrypted-text platform OR named secure portal OR named voice with no PHI in voicemail), AND (c) named risk acknowledgement when the patient explicitly opts into a less-secure channel. Surface a watch item on any outbound communication using SMS to a non-validated number without consent on file, AND any voicemail logged against a number marked 'shared family line' that named the patient's named therapy.